When was AtriAN founded?

AtriAN was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is AtriAN located?

AtriAN is headquartered in Galway, Ireland.

Is AtriAN a funded company?

AtriAN is a funded company, having raised a total of $2.56M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 24, 2019.

When was the latest funding round of AtriAN?

AtriAN's latest funding was a $***** Grant (prize money) round on Apr 30, 2022, with participation from 1 investor.

Where does AtriAN rank among its competitors?

AtriAN ranks 10th amongst 17 active competitors, of which 11 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Pulsecare Medical Technology, which secured $14M in Nov, 2025.

Who are the top competitors of AtriAN?

AtriAN's top competitors include Kardium, Galvanize and Argá Medtech. Among them, Pulsecare Medical Technology secured the most recent funding round in November, 2025.

AtriAN - 2026 Company Profile, Team, Funding & Competitors

AtriAN is a seed company based in Galway (Ireland), founded in 2017 by Ken Coffey and Barry O'brien. It operates as a Developing the device that targets to atrial fibrillation. AtriAN has raised $2.56M in funding from Western Development Commission. The company has 17 active competitors, including 11 funded and 3 that have exited. Its top competitors include companies like Kardium, Galvanize and Argá Medtech.

Company Details

Atrian Medical is developing the device that targets to atrial fibrillation. Atrian uses gentle energy and micro pulsed electric fields (mPEF) that ablate the hyperactivity of the heart. The device also targets the hyperactive neuronal cells-Ganglionated Plexi (GPs) that help to regulate the atrial rhythm.

Key Metrics

Founded Year

2017

Location

Galway, Ireland

Stage

Seed

Total Funding

$2.56M in 3 rounds

Latest Funding Round

Grant (prize money), Apr 30, 2022, $*****

Investors

Western Development Commission & 5 more

Ranked

10^th among 17 active competitors

Similar Companies

Kardium & 15 more

View AtriAN's full profile

AtriAN has raised a total funding of $2.56M over 3 rounds. Its first funding round was on Oct 24, 2019. Its latest funding round was a Grant (prize money) round on Apr 30, 2022 for $*****. 1 investor participated in its latest round. AtriAN has 6 institutional investors.

Here is the list of recent funding rounds of AtriAN:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2022	5863621	Grant (prize money)	2023862	4245863	5729705	7774323
Nov 01, 2019	6948554	Grant (prize money)	4402698	1943026	5844737	Europa
Oct 24, 2019	9419993	Seed	4915479	2244823	Western Development Commission	Mayo Clinic Ventures & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of AtriAN's funding rounds and investors

The founders of AtriAN are Ken Coffey and Barry O'brien.

Here are the details of AtriAN's key team members:

Ken Coffey: Co-Founder of AtriAN.
Contact Info: 1 email address
Barry O'brien: Chief Technology Officer and Co-Founder of AtriAN.

View details of AtriAN's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AtriAN include Kardium, Galvanize and Argá Medtech. Here is the list of Top 10 competitors of AtriAN, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Kardium 2007, Burnaby (Canada), Series C	Developer of ablation device for atrial fibrillation	$471M	Fidelity Investments, T. Rowe Price & 10 others	64/100
2nd	Galvanize 2020, San Carlos (United States), Series C	Developer of pulsed electric field systems for various medical indications	$210M	Fidelity Investments, Sofinnova Partners ... & 11 others	58/100
3rd	Argá Medtech 2020, Epalinges (Switzerland), Series B	Developer of medical devices for treating cardiac arrhythmias	$58.5M	Advent Life Sciences, Earlybird & 1 others	57/100
4th	Field Medical 2022, Encinitas (United States), Series B	Developer of device for the treatment of heart arrhythmia conditions	$89M	BioStar Capital, Cue Growth Partners	56/100
5th	Affera 2014, Boston (United States), Acquired	Developer of devices to treat heart rhythm disorders	-	Innogest Capital, Bain Capital Life Sciences ... & 4 others	53/100
6th	Pulsecare Medical Technology 2021, Shenzhen (China), Series A	Developer of medical device solutions for heart and vascular care	$14M	Oriza Holdings, Loayal Valley Capital & 3 others	50/100
7th	Pulse Biosciences 2014, Burlingame (United States), Acquired	Developer of a platform technology called Nano-Pulse Electro-Signaling	$8M	MDB Capital, Sea Purity Investments & 1 others	49/100
8th	EnChannel Medical 2020, Ladera Ranch (United States), Series B	Developer of medical device for cardiac disorders	$110M	LAV, DragonBall Capital & 2 others	49/100
9th	Farapulse 2014, Menlo Park (United States), Series C	Advanced cardiac ablation solutions for atrial fibrillation treatment	$36.3M	F-Prime Capital, Boston Scientific & 3 others	44/100
10th	AtriAN 2017, Galway (Ireland), Seed	Developing the device that targets to atrial fibrillation	$2.56M	Mayo Clinic Ventures, Atlantic Bridge & 4 others	41/100